Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?

European Respiratory Journal

Volumn 48, Issue 2, 2016, Pages 582-585

  Guglielmetti, Lorenzo ^a,b   Le Dû, Damien ^a   Veziris, Nicolas ^b,c   Caumes, Eric ^c   Marigot Outtandy, Dhiba ^a,d   Yazdanpanah, Yazdan ^e   Robert, Jérôme ^b,c   Fréchet Jachym, Mathilde ^a  

^a Centre Hospitalier de Bligny   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d RAYMOND POINCARÉ HOSPITAL   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; BEDAQUILINE; CARBAPENEM; CLAVULANIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM ISOLATE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LETTER; LUNG CAVITY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPUTUM CULTURE; TREATMENT DURATION; TREATMENT RESPONSE; COMPARATIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84980023443     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00411-2016     Document Type: Letter

References (15)

1. Pontali E, Sotgiu G, D'Ambrosio L, et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394-402.
2. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
3. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292.
4. van Halsema C, Humphreys S, Bonington A. Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. Eur Respir J 2014; 43: 292-294.
5. Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015; 19: 979-985.
6. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993.
7. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
8. Guglielmetti L, Le D? D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188-194.
9. World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug-resistant Tuberculosis: Interim Policy Guidance. WHO/HTM/TB/2013.6. Geneva, World Health Organization, 2013.
10. Canetti G, Rist N, Grosset J. Mesure de la sensibilité du bacille tuberculeux aux drogues antibacillaires par la méthode des proportions [Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation]. Rev Tuberc Pneumol 1963; 27: 217-272.
11. Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med 2015; 3: 201-209.
12. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 2831-2835.
13. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
14. Balabanova Y, Ignatyeva O, Fiebig L, et al. Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference? Thorax 2016; in press [DOI: 10.1136/thoraxjnl-2015-207638].
15. Bernard C, Veziris N, Brossier F, et al. Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015; 59: 1519-1524.